SPIMACO was established in the year 1986 in the Kingdom of Saudi Arabia (as a Public Joint Stock Company). SPIMACO and its subsidiaries are engaged in medical and pharmaceutical production including manufacturing, producing, developing, marketing, selling and distributing pharmaceutical raw materials, medical and pharmaceutical solutions, production supplies, medical and pharmaceutical supplies and equipment in addition to producing medical consumables in addition to other investment in many companies inside and outside the Kingdom of Saudi Arabia, SPIMACO  capital amounts to SAR 1.2 bilion,ACDIMA owns  20.488% SPIMACO Addwaeih’s core business is medical and pharmaceutical, which includes development, manufacturing and sales of pharmaceutical products and medical appliances. Moreover, SPIMACO also has ownership in number of joint stock ans limited liabilities companies inside and outside the Kingdom . SPIMACO has developed a strong position in Saudi Arabia and is well positioned to sustain its growth and have a sound platform to serve export markets. SPIMACO main manufacturing facility – Al–Qassim Pharmaceutical Plant was planned , constructed and equipped up to the highest quality levels. SPIMACO earned a lot of national quality awards and attained major international certifications. SPIMACO serves successfully several markets locally and internationally and have built superior relations with regulatory bodies and the medical professions at large. The heavy investments in regulatory, marketing, sales and international alliances gave SPIMACO the market capabilities to prosper and overtake a lot of competitors. An important and distinctive advantage of SPIMACO strategy is its relations with multinational companies. A very flexible, objective and versatile approach let to a multitude of relationships that served the interests of all parties. SPIMACO is a successful joint stock company and it has one of the most actively traded shares in the Saudi stock market.